NVS

Another failure. https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-halts-als-drug-development-after-mid-stage-trial-failure-2026-09-16/

Waiting for their Sjögrens drug to hit. As a long term sufferer, it’ll be a good day.

Last week it was ~$163. This trading market just nukes your company when bad news hits. You are torched when you swing and miss

Ianalumab ???

I am not short MRNA or any stock I only buy and hold not even a trader!

I love ImmunityBio IBRX

https://ir.immunitybio.com/news-releases/news-release-details/asco-report-pioneering-treatment-lymphopenia-significant-overall

https://immunitybio.com/

https://immunitybio.com/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer/

https://immunitybio.com/pipeline/

Stock is going nowhere

FDA approved and stock drops ??

manufacturer of xolair, which can reduce the risk of extreme allergic reaction in children. Amazing

$NVS earnings tomorrow before market open. What do ya think gonna happen? ?or?

$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.